Titan Biotech Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Titan Biotech Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 89% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 88% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹94Over the last 3 years, every ₹100 of reported profit came with ₹94 of operating cash.
Lower than 56% of Healthcare companies in India.
Self-Funding Ratio
2.0×Over the last 3 years its own operating cash covered its investment spending (capex) 2.0 times.
Higher than 68% of Healthcare companies in India.
Cash Locked Ratio
₹32For every ₹100 of sales, ₹32 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹32 tied up three years earlier.
More money tied up than 64% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹8Sales grew 43% in 3 years; of every extra ₹100 of sales, ₹8 became extra profit.
Lower than 72% of Healthcare companies in India.
Asset Productivity Ratio
+43% / +59%In 3 years sales changed by +43% while total assets changed by +59%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
9.1×Debt due within a year is covered 9.1 times by its yearly operating cash.
Higher than 75% of Healthcare companies in India.
Cash Cushion Ratio
−0%Debt, after subtracting cash, equals 0% of its market value (net debt).
Higher than 58% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 88% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 89% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Titan Biotech Limited owes ₹0.15 for every ₹1 it owns. Net profit rose 39% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
39.7Investors pay ₹39.7 for every ₹1 of Titan Biotech Limited's yearly profit, higher than 56% of Healthcare companies in India.
P/B ratio
7.42The share price is 7.42 times Titan Biotech Limited's book value per share, higher than 76% of Healthcare companies in India.
Market cap
₹1,346 CrThe total market value of all of Titan Biotech Limited's shares at today's price (share price × number of shares), smaller than 75% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹182 CrWhat Titan Biotech Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹43.94Net worth divided by the number of shares. The share price of ₹325.85 is 7.4 times this, which is the P/B above.
Return on equity (ROE)
18.7%Titan Biotech Limited earned 18.7% on its shareholders' money over the last year, higher than 75% of Healthcare companies in India.
Owes vs Owns
0.15×Titan Biotech Limited owes ₹0.15 for every ₹1 it owns (low), lower than 91% of Healthcare companies in India.
Dividend yield
0.13%Titan Biotech Limited pays 0.13% of its share price as dividends a year, lower than 82% of dividend-paying Healthcare companies in India.
Revenue growth
+32%Revenue rose 32% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
+39%Net profit rose 39% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit margin
14.5%Titan Biotech Limited keeps ₹14 of every ₹100 of revenue as net profit.
Cash quality
1.02×Cash from Titan Biotech Limited's business was 1.02× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
46.1×Titan Biotech Limited's operating profit covered its interest costs 46.1 times in the year to Mar 2026.
Cash vs debt
Net debtTitan Biotech Limited had ₹4 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Titan Biotech Limited's P/E ratio?
Investors pay ₹39.7 for every ₹1 of Titan Biotech Limited's yearly profit, higher than 56% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Titan Biotech Limited: ₹1,346 Cr ÷ ₹182 Cr (31 Mar 2026) = 7.4.
What is Titan Biotech Limited's return on equity?
Titan Biotech Limited earned 18.7% on its shareholders' money over the last year, higher than 75% of Healthcare companies in India.
How much does Titan Biotech Limited owe compared with what it owns?
Titan Biotech Limited owes ₹0.15 for every ₹1 it owns (low), lower than 91% of Healthcare companies in India.
Does Titan Biotech Limited pay a dividend?
Yes. Titan Biotech Limited pays 0.13% of its share price as dividends a year, lower than 82% of dividend-paying Healthcare companies in India.
Is Titan Biotech Limited's revenue growing?
Revenue rose 32% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.